CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 23, 2006--Gwathmey, Inc., a pre-clinical contract research organization and biotechnology company specializing in arthritis, cancer, cardiovascular disease, diabetes, obesity, and infectious diseases, announced today that Gregory J. Davenport, Ph.D., has joined Gwathmey as Executive Vice President. Dr. Davenport has over 12 years experience in the biopharmaceutical industry. Prior to joining Gwathmey, Dr. Davenport was President, Biodefense Division, of a public biopharmaceutical company where he was responsible for development of two recombinant vaccines and a therapeutic, strategies aimed at winning federal funding, and establishing strategic relationships with commercial, government and academic partners. His efforts lead to the initiation of a Phase I clinical trial, substantial new government funding and strategic partnerships with major companies such Dowpharma, Cambrex, and the United States Army Medical Research Institute of Infectious Disease.
